V A Abrikosova, Y A Mokrushina, L A Ovchinnikova, E N Larina, S S Terekhov, M N Baranova, Y A Lomakin, D S Balabashin, T V Bobik, E N Kaliberda, V D Knorre, M V Shpilevaya, T K Aliev, D G Deryabin, A E Karamova, A A Kubanov, M P Kirpichnikov, I V Smirnov
Pemphigus vulgaris is a severe, socially significant autoimmune disease associated with autoantibodies to the desmoglein 3 antigen. The disease affects all age groups, beginning at 18 years of age; the mortality rate of pemphigus can reach as high as 50%, depending on a patient's age and a number of other factors. There is no highly selective or personalized therapy for pemphigus vulgaris at the moment. One of the well-known therapeutic approaches to the disease is to use rituximab, an anti-CD20 antibody that can help achieve B cell depletion in peripheral blood...
2023: Acta Naturae